New Haven Pharmaceuticals Receives $2M Venture Loan Facility from Horizon Technology Finance

New Haven Pharmaceuticals, Inc., a Guilford, CT-based developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications, closed a $2m venture loan facility with Horizon Technology Finance Corporation (Nasdaq: HRZN).

The company intends to use facility for working capital purposes.

Led by Patrick P. Fourteau, President & CEO and Harry H. Penner, Jr. , Executive Chairman, New Haven Pharmaceuticals is a specialty pharmaceutical company developing proprietary prescription drug products based on proprietary controlled-release technologies, as well as intellectual property licensed from Yale University.



Join the discussion